MTOR and non-small cell lung carcinoma: Furthermore, the Western blot analysis revealed a dose-dependent reduction in the percentages of p-PI3K/PI3K, p-AKT/AKT, and p-mTOR/mTOR in PA-treated NSCLC cells (Figure 3G,H).